Isofol announces first half 2026 interim report
The biotech firm reports zero revenue and a net loss of 30.7 million SEK. Clinical development of arfolitixorin continues with new German trial sites.
See the latest news and media coverage for Isofol. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotechnology company developing a folate-based cancer drug
isofolmedical.comLast updated
In short: Isofol began final dose cohort as patients became eligible for surgery, posted SEK 30.7M H1 loss
The biotech firm reports zero revenue and a net loss of 30.7 million SEK. Clinical development of arfolitixorin continues with new German trial sites.
Principal investigator Sebastian Stintzing reports positive interim phase Ib results with tumor shrinkage and no dose-limiting side effects for the drug candidate.
The report shows financial results and progress in clinical study of arfolitixorin.
The company reported a net loss of SEK 15 million but secured nearly SEK 19 million through warrant exercises and gained regulatory approval for study expansions.
Isofol Medical AB has published its financial results for the second quarter and the first half ended June 30, 2026. For the second quarter...
GOTHENBURG, Sweden, July 8, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has completed the third dose level in...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive...
GOTHENBURG, Sweden, April 15, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the German regulatory authority BfArM has approved an optimized...
Track Isofol and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.